Last reviewed 2026-04-19 · How we verify

LOXIGLUMIDE

Phase 2 active Small molecule

LOXIGLUMIDE is a loxiglumide drug. It is currently in Phase 2 development.

Loxiglumide works by binding to the cholecystokinin receptor type A, which helps to slow down gastric emptying and reduce symptoms of certain gastrointestinal disorders.

Loxiglumide is a small molecule drug that targets the cholecystokinin receptor type A. It is classified as a loxiglumide, but its commercial status and approved indications are unknown. The drug has a half-life of 5.2 hours, but its bioavailability and off-patent status are not specified. As a result, its availability and use are limited. Further research is needed to determine its potential as a therapeutic agent.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LOXIGLUMIDE
Drug class	loxiglumide
Target	Cholecystokinin receptor type A, Cholecystokinin receptor type A
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	Phase 2

Mechanism of action

Imagine your stomach is a bucket that fills up with food. Loxiglumide helps to slow down the flow of food from the stomach into the small intestine, giving your body more time to digest it properly. This can help to reduce symptoms of conditions like gastroparesis, where the stomach takes too long to empty its contents.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LOXIGLUMIDE CI brief — competitive landscape report
LOXIGLUMIDE updates RSS · CI watch RSS

Frequently asked questions about LOXIGLUMIDE

What is LOXIGLUMIDE?

LOXIGLUMIDE is a loxiglumide drug.

How does LOXIGLUMIDE work?

Loxiglumide works by binding to the cholecystokinin receptor type A, which helps to slow down gastric emptying and reduce symptoms of certain gastrointestinal disorders.

What drug class is LOXIGLUMIDE in?

LOXIGLUMIDE belongs to the loxiglumide class. See all loxiglumide drugs at /class/loxiglumide.

What development phase is LOXIGLUMIDE in?

LOXIGLUMIDE is in Phase 2.

What does LOXIGLUMIDE target?

LOXIGLUMIDE targets Cholecystokinin receptor type A, Cholecystokinin receptor type A and is a loxiglumide.

Drug class: All loxiglumide drugs
Target: All drugs targeting Cholecystokinin receptor type A, Cholecystokinin receptor type A
Therapeutic area: All drugs in Gastroenterology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing